Vitality Watch

⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.

Mentioned 1× · first seen 27-sep-2026 · last seen 27-sep-2026

AT2 Receptor (AT2R) in Cardiac Aging and Senescence

Current understanding

The Type 2 Angiotensin II receptor (AT2R) is proposed as a counter-regulatory arm of the renin–angiotensin system whose loss accelerates cardiac senescence, fibrosis, and NLRP3-inflammasome activation in aged mice, with a reported ~5-month shortening of median lifespan versus wild-type [animal-model]. Human translation is untested, and the pathway sits adjacent to — but distinct from — the AT1R-blocker cardioprotection literature that dominates current clinical RAS pharmacology.

Evidence log

Open questions

Related

Contributing findings

pubmed preclinical
Type 2 Angiotensin II receptor (AT2R) deficiency exacerbates cardiac senescence and fibrosis in aging mice.
25-sep-2026 novelty 3 per-area 3 introduces

build build 880 · 2bcef25 · 2026-11-18